Precipitation of ceftriaxone-calcium can also occur when Rocephin is mixed with calcium-containing solutions in the same IV administration line. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and institution of appropriate management. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. A cofactor role of Rocephin-related biliary precipitation cannot be ruled out.Considering the maximum duration of treatment and the class of the compound, carcinogenicity studies with ceftriaxone in animals have not been performed.

Data are generally insufficient to allow an estimate of incidence or to establish causation.A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving Rocephin and calcium-containing fluids.

The potentially lower clinical cure rate of Rocephin should be balanced against the potential advantages of parenteral therapy (see The preoperative administration of a single 1 gm dose of Rocephin may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (egWhen administered prior to surgical procedures for which it is indicated, a single 1 gm dose of Rocephin provides protection from most infections due to susceptible organisms throughout the course of the procedure.Rocephin is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilisStaphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenesEscherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii,URINARY TRACT INFECTIONS (complicated and uncomplicated)Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganiiUNCOMPLICATED GONORRHEA (cervical/urethral and rectal)Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzaeStaphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniaeEscherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, ClostridiumGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONSMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard -Tenth Edition.Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational SupplementPerformance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth EditionMethods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eight Edition.We comply with the HONcode standard for trustworthy health information - Particulate formation can result.Ceftriaxone has been shown to be compatible with FlagylVancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with ceftriaxone in admixtures. These adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the human exposure to bimatoprost 0.03% dosed bilaterally once daily (based on blood AUC levels).In pre/postnatal development studies, administration of bimatoprost to pregnant rats from organogenesis to the end of lactation resulted in reduced gestation length and fetal body weight, and increased fetal and pup mortality at oral doses at least 41 times the human systemic exposure to bimatoprost 0.03% dosed bilaterally once daily (based on blood AUC levels). Mechanism of Action: Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Concentrations between 10 mg/mL and 40 mg/mL are recommended; however, lower concentrations may be used if desired. Patients may be asymptomatic or may develop symptoms of gallbladder disease.

Careful observation of the patient is essential. There have been no similar reports in patients other than neonates.In addition to the adverse reactions listed above which have been observed in patients treated with ceftriaxone, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics:Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. It may also be used to increase the size of the eyelashes. Caution should be exercised when Rocephin is administered to a nursing woman.Safety and effectiveness of Rocephin in neonates, infants and pediatric patients have been established for the dosages described in the Of the total number of subjects in clinical studies of Rocephin, 32% were 60 and over.

Discontinue ceftriaxone sodium in patients who develop signs and symptoms suggestive of gallbladder disease and/or the sonographic findings described above.Ceftriaxone-calcium precipitates in the urinary tract have been observed in patients receiving Rocephin and may be detected as sonographic abnormalities.